Capricor <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Faces Class Action Lawsuit Amid Allegations of Securities Fraud and FDA Setbacks
Capricor Therapeutics Inc. is facing a class action securities lawsuit following allegations of securities fraud. The lawsuit, filed on behalf of investors who suffered financial losses, claims that between October 9, 2024, and July 10, 2025, the company and its executives disseminated false and misleading information regarding its lead cell therapy candidate drug, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy. The lawsuit contends that Capricor provided overwhelmingly positive statements about the potential to obtain a Biologics License Application from the FDA while concealing adverse facts about the drug's safety and efficacy from its Phase 2 HOPE-2 trial. The announcement of a Complete Response Letter from the FDA, which cited the need for additional clinical data, led to a significant drop in Capricor's stock price. Levi & Korsinsky, LLP, a law firm with a strong track record in securities litigation, is handling the case.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1068758) on September 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.